866-997-4948(US-Canada Toll Free)

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jun 2015

Category :

Cancer

No. of Pages : 268 Pages


Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2015, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Bile Duct Cancer (Cholangiocarcinoma) Overview 8
Therapeutics Development 9
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 9
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 10
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 11
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 15
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 19
Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 22
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 23
4SC AG 23
Agios Pharmaceuticals, Inc. 24
Ariad Pharmaceuticals, Inc. 25
ArQule, Inc. 26
Array BioPharma Inc. 27
Arrien Pharmaceuticals, LLC 28
AstraZeneca PLC 29
Bayer AG 30
Boston Biomedical, Inc. 31
Bristol-Myers Squibb Company 32
Celgene Corporation 33
CellAct Pharma GmbH 34
Concordia Healthcare Corp. 35
Cornerstone Pharmaceuticals, Inc. 36
Delcath Systems, Inc. 37
Eli Lilly and Company 38
Exelixis, Inc. 39
F. Hoffmann-La Roche Ltd. 40
GlaxoSmithKline Plc 41
Komipharm International Co., Ltd. 42
Mebiopharm Co., Ltd. 43
Merck & Co., Inc. 44
Merrimack Pharmaceuticals, Inc. 45
Novartis AG 46
NuCana BioMed Limited 47
OncoTherapy Science, Inc. 48
Panacea Pharmaceuticals, Inc. 49
PCI Biotech AS 50
Pfizer Inc. 51
Provecs Medical GmbH 52
Sanofi 53
Senhwa Biosciences, Inc. 54
Spectrum Pharmaceuticals, Inc. 55
Threshold Pharmaceuticals, Inc. 56
VasGene Therapeutics, Inc. 57
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 63
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 70
AG-120 - Drug Profile 72
ARN-5032 - Drug Profile 74
ARQ-087 - Drug Profile 75
BBI-503 - Drug Profile 76
BGJ-398 - Drug Profile 78
binimetinib - Drug Profile 79
cabozantinib s-malate - Drug Profile 84
CAP-7.1 - Drug Profile 87
CC-90007 - Drug Profile 89
CPI-613 - Drug Profile 92
dasatinib - Drug Profile 94
DKN-01 - Drug Profile 97
elpamotide - Drug Profile 99
evofosfamide - Drug Profile 101
gemcitabine hydrochloride - Drug Profile 109
Im-01 - Drug Profile 110
KML-001 - Drug Profile 111
MBPY-005 - Drug Profile 113
melphalan - Drug Profile 114
merestinib - Drug Profile 116
MK-2206 - Drug Profile 117
NUC-1031 - Drug Profile 120
OCVC-01 - Drug Profile 122
paclitaxel albumin bound - Drug Profile 123
PAN-622 - Drug Profile 127
pembrolizumab - Drug Profile 128
ponatinib hydrochloride - Drug Profile 135
porfimer sodium - Drug Profile 137
Recombinant Protein to Antagonize EphB4 Receptor for Oncology - Drug Profile 138
refametinib - Drug Profile 140
regorafenib - Drug Profile 143
resminostat - Drug Profile 146
RRX-001 - Drug Profile 151
SAR-408701 - Drug Profile 153
selumetinib sulfate - Drug Profile 154
seribantumab - Drug Profile 157
silmitasertib - Drug Profile 160
SPI-1620 - Drug Profile 162
sunitinib malate - Drug Profile 163
trametinib dimethyl sulfoxide - Drug Profile 167
Vaccine for Metastatic Cholangiocarcinoma - Drug Profile 170
vemurafenib - Drug Profile 171
Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 174
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 253
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 255
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 256
Featured News & Press Releases 256

Appendix 264
Methodology 264
Coverage 264
Secondary Research 264
Primary Research 264
Expert Panel Validation 264
Contact Us 264
Disclaimer 265

List of Table


Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015 12
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2015 26
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2015 27
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 28
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H1 2015 29
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H1 2015 30
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 31
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca PLC, H1 2015 32
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2015 33
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H1 2015 34
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2015 35
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H1 2015 36
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2015 37
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H1 2015 38
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 39
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H1 2015 40
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2015 41
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2015 42
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 43
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by GlaxoSmithKline Plc, H1 2015 44
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co., Ltd., H1 2015 45
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co., Ltd., H1 2015 46
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co., Inc., H1 2015 47
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 48
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H1 2015 49
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H1 2015 50
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H1 2015 51
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 52
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech AS, H1 2015 53
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc., H1 2015 54
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2015 55
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H1 2015 56
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H1 2015 57
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 58
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 59
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics, Inc., H1 2015 60
Assessment by Monotherapy Products, H1 2015 61
Assessment by Combination Products, H1 2015 62
Number of Products by Stage and Target, H1 2015 64
Number of Products by Stage and Mechanism of Action, H1 2015 67
Number of Products by Stage and Route of Administration, H1 2015 70
Number of Products by Stage and Molecule Type, H1 2015 72
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2015 177
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2015 256
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H1 2015 257
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2015 258

List of Chart


Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015 12
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 20
Assessment by Monotherapy Products, H1 2015 61
Number of Products by Top 10 Targets, H1 2015 63
Number of Products by Stage and Top 10 Targets, H1 2015 63
Number of Products by Top 10 Mechanism of Actions, H1 2015 66
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 66
Number of Products by Top 10 Routes of Administration, H1 2015 69
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 70
Number of Products by Top 10 Molecule Types, H1 2015 71
Number of Products by Stage and Top 10 Molecule Types, H1 2015 72

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *